


REMARKS

Currently claims 1-3, 5-7, 12, 14-17, 21 and 23 are pending. The Examiner has required restriction to one of two groups. In response to such restriction, Applicants wish to proceed as follows.

Applicants elect Group I (claims 1-3, 5, 7, 12, 14-17, and 23), drawn to a chemical compound, a pharmaceutical composition, and a process for preparing using a chemical compound of Formula I, for proceeding with prosecution on the merits.

Applicants elect the single species set forth in Claim 16, as follows:

N-[4-(3-Piperidin-1-ylpropoxy)-benzoyl]-5-fluoroisoindoline or its salt




The species radicals requested to be defined by the Examiner are b, h, g, and R⁴. In the above compound: b=0; there is no h or g; and R⁴ is -(CH₂)_qNR¹¹R¹², where q is 3.

Group I claims readable thereon include 1, 2, 3, 12, 15, 16, 17, and 23.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,

Date: 31 October 2007


Bonnie L. Deppenbrock
Attorney for Applicant
Registration No. 28,209

Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-1577
Facsimile: (919) 483-7988